Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

Katrijn Grupping, Laura Campora, Martine Douha, Thomas C Heineman, Nicola P Klein, Himal Lal, James Peterson, Ilse Vastiau, Lidia Oostvogels, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C Heineman, Nicola P Klein, Himal Lal, James Peterson, Ilse Vastiau, Lidia Oostvogels

Abstract

Background: Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years. Revaccination may renew protection. We assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL recipients and ZVL-naive individuals (HZ-NonVac).

Methods: In an open-label, multicenter study, adults ≥65 years of age, vaccinated with ZVL ≥5 years previously (HZ-PreVac), were matched to ZVL-naive adults (HZ-NonVac). Participants received 2 doses of HZ/su 2 months apart. The primary objective of noninferiority of the humoral immune response 1 month post-dose 2 was considered demonstrated if the upper limit of the 95% confidence interval (CI) of the adjusted anti-glycoprotein E geometric mean concentration (GMC) ratio of HZ-NonVac over HZ-PreVac was <1.5. HZ/su cellular immunogenicity, reactogenicity, and safety were also assessed.

Results: In 430 participants, humoral immune response to HZ/su was noninferior in HZ-PreVac compared with HZ-NonVac (adjusted GMC ratio, 1.04 [95% CI, .92-1.17]). Cellular immunogenicity, reactogenicity, and safety appeared to be comparable between groups. HZ/su was well-tolerated, with no safety concerns raised within 1 month post-dose 2.

Conclusions: HZ/su induces a strong immune response irrespective of prior vaccination with ZVL, and may be an attractive option to revaccinate prior ZVL recipients.

Clinical trials registration: NCT02581410.

Keywords: HZ/su adjuvanted herpes zoster subunit vaccine; herpes zoster; immune response; live attenuated zoster vaccine Zostavax; revaccination.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Study design. Before the first participant was vaccinated, potential participants were screened for eligibility and matching purposes. Matched participants were included in the study. During the active phase of the study, participants visited the study center at specified timepoints for a blood draw to determine immune parameters (months 0, 1, and 3), and to receive the study vaccine (months 0 and 2). Only data collected during the active phase of the study are reported in this manuscript. The safety follow-up was expected to continue until August 2017. During this safety follow-up, participants are being followed for safety through monthly phone calls. A final blood draw is scheduled to take place at 12 months after the second dose of study vaccine. Abbreviations: HZ-NonVac, participants who never received the live attenuated zoster vaccine; HZ-PreVac, participants who received the live attenuated zoster vaccine ≥5 years prior to study start; HZ/su, herpes zoster subunit candidate vaccine.
Figure 2.
Figure 2.
Participant disposition. Potential participants were first screened and matching variables were collected (see Figure 1). Only matched participants were vaccinated with herpes zoster subunit candidate vaccine (see Supplementary Table 1 for additional information on matching). Abbreviations: HZ-NonVac, participants who never received the live attenuated zoster vaccine; HZ-PreVac, participants who received live attenuated zoster vaccine ≥5 years prior to study start; SAE, serious adverse event.
Figure 3.
Figure 3.
Humoral and cellular immune response to herpes zoster subunit candidate vaccine (HZ/su) (according to protocol cohort for immunogenicity). A, Humoral immune response to HZ/su vaccination. Anti–glycoprotein E (gE) antibody concentrations were determined by enzyme-linked immunosorbent assay. Data are geometric mean concentrations (GMCs [mIU/mL]) and error bars indicate 95% confidence intervals. B, Cellular immune response to HZ/su vaccination. The gE-specific CD4+ cells expressing at least 2 activation markers (CD42+) were determined by intracellular staining and flow cytometry. Data are median cell counts per 106 total peripheral blood mononuclear cells. Light bars indicate participants who received the live attenuated zoster vaccine ≥5 years prior to study start (HZ-PreVac group); dark bars indicate participants who never received the live attenuated zoster vaccine (HZ-NonVac group). Abbreviations: M0 = pre vaccination; M1, one month post-dose 1; M3, one month post-dose 2.
Figure 4.
Figure 4.
Solicited adverse events (AEs) after vaccination doses (total vaccinated cohort). A, Percentage of participants reporting local solicited AEs after herpes zoster subunit candidate vaccine (HZ/su) dose 1. B, Percentage of participants reporting local solicited AEs after HZ/su dose 2. C, Percentage of participants reporting related systemic solicited AEs after HZ/su dose 1. D, Percentage of participants reporting related systemic solicited AEs after HZ/su dose 2. Light bars indicate participants who received the live attenuated zoster vaccine ≥5 years prior to study start (HZ-PreVac group); dark bars indicate participants who never received the live attenuated zoster vaccine (HZ-NonVac group). Striped sections indicate grade 3 solicited AEs. Error bars indicate 95% confidence intervals.

References

    1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013; 369:255–63.
    1. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ 2000; 321:778–9.
    1. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109:S13–7.
    1. Weinberg A, Zhang JH, Oxman MN, et al. US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068–77.
    1. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48(Suppl 1):S2–7.
    1. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M. Immunosenescence and infectious diseases. Microbes Infect 2001; 3:851–7.
    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833.
    1. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015; 15:502.
    1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1–30; quiz CE2–4.
    1. Kawai K, Rampakakis E, Tsai TF, et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. Int J Infect Dis 2015; 34:126–31.
    1. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341–9.
    1. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009:CD006866. doi:10.1002/14651858.CD006866.
    1. Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 2015; 15:533.
    1. Schmader KE, Levin MJ, Gnann JW, Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922–8.
    1. Oxman MN, Levin MJ, Johnson GR, et al. Shingles Prevention Study Group A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.
    1. Schmader KE, Oxman MN, Levin MJ, et al. Shingles Prevention Study Group Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320–8.
    1. Morrison VA, Johnson GR, Schmader KE, et al. Shingles Prevention Study Group Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900–9.
    1. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522–31.
    1. Vafai A. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine 1995; 13:1336–8.
    1. Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193:1920–30.
    1. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471–86.
    1. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32:1745–53.
    1. Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis 2013; 208:1953–61.
    1. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280–90.
    1. Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 2016; 34:863–8.
    1. Lal H, Cunningham AL, Godeaux O, et al. ZOE-50 Study Group Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087–96.
    1. Cunningham AL, Lal H, Kovac M, et al. ZOE-70 Study Group Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:1019–32.
    1. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016; 213:1872–5.
    1. Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 2016; 213:14–22.
    1. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Zoster-015 HZ/su Study Group Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211:1279–87.
    1. Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults. Hum Vaccin Immunother 2013; 9:1425–9.
    1. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 2014; 124:2921–9.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj